Multicentricity in different molecular subtypes of breast cancer: A cross-sectional study in Isfahan


1 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Breast cancer is the most common cancer leading to death in women. Women with multicentric breast cancer were reported more likely to have poor prognosis. Here, we decided to study and compare the frequency distribution of multicentricity in different subtypes of breast cancer.
Materials and Methods: This is a cross-sectional study that was performed in 2019–20 on medical records and breast pathology reports of 250 patients who undergone mastectomy due to breast cancer. Demographic data of all patients including age, along with other medical data such as menstruation condition, breast cancer grade, multicentricity status, stage, and expression of estrogen receptor (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) receptors were collected from medical records. Samples were divided into four subtypes of Luminal B, Luminal A, HER2 expressing, and basal-like.
Results: The mean age of patients was 50.21 ± 11.15 years. Ninety-five patients (38%) had multicentricity and HER2 expressing (48.5%) and Luminal A (41.4%) were most common in patients with multicentricity. In addition, basal-like group presented with least multicentricity (13.5%) among the subtypes (P = 0.008). We also showed significant increased chances of multicentricity in Luminal B (odds ratio [OR] = 3.782) (P = 0.033), Luminal A (OR = 5.164) (P = 0.002), and HER2-expressing group (OR = 5.393) (P = 0.011).
Conclusions: Taken together, we showed significantly increased chances of multicentricity in patients with HER2-expression, Luminal A, and Luminal B groups compared to basal-like group or triple negative. These results were in line with most previous studies; however, we showed higher rates of multicentricity among our population compared to some previous reports.


Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019;321:288-300.  Back to cited text no. 1
Sancho-Garnier H, Colonna M. Breast cancer epidemiology. Presse Med 2019;48:1076-84.  Back to cited text no. 2
Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME. Epidemiology and histopathology of breast cancer in Iran versus other Middle Eastern countries. Middle East J Cancer 2018;9:243-51.  Back to cited text no. 3
Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol 2015;39:519-27.  Back to cited text no. 4
Enayatrad M, Amoori N, Salehiniya H. Epidemiology and trends in breast cancer mortality in Iran. Iran J Public Health 2015;44:430-1.  Back to cited text no. 5
Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 2017;4:228.  Back to cited text no. 6
Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev 2017;1:CD010802.  Back to cited text no. 7
Calhoun BC. Core needle biopsy of the breast: An evaluation of contemporary data. Surg Pathol Clin 2018;11:1-16.  Back to cited text no. 8
Waks AG, Winer EP. Breast cancer treatment. JAMA 2019;321:316.  Back to cited text no. 9
Schrijver WA, Van Der Groep P, Hoefnagel LD, Ter Hoeve ND, Peeters T, Moelans CB, et al. Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Mod Pathol 2016;29:1460-70.  Back to cited text no. 10
Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer 2015;22:615-25.  Back to cited text no. 11
Akbulut H, Ersoy YE, Coskunpinar E, Gucin Z, Yildiz S, Malya FU, et al. The role of miRNAs as a predictor of multicentricity in breast cancer. Mol Biol Rep 2019;46:1787-96.  Back to cited text no. 12
Iamurri AP, Ponziani M, Macchini M, Fogante M, Pistelli M, De Lisa M, et al. Evaluation of multifocality and multicentricity with breast magnetic resonance imaging in each breast cancer subtype. Clin Breast Cancer 2018;18: e231-5.  Back to cited text no. 13
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26: v8-30.  Back to cited text no. 14
Ha R, Jin B, Mango V, Friedlander L, Miloshev V, Malak S, et al. Breast cancer molecular subtype as a predictor of the utility of preoperative MRI. Am J Roentgenol 2015;204:1354-60.  Back to cited text no. 15
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003;8:307-25.  Back to cited text no. 16
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-47.  Back to cited text no. 17
Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, Osoth PP. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women. Asian Pac J Cancer Prev 2012;13:459-62.  Back to cited text no. 18
Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009;16:2705-10.  Back to cited text no. 19
Vasconcelos I, Hussainzada A, Berger S, Fietze E, Linke J, Siedentopf F, et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease-free survival. Breast 2016;29:181-5.  Back to cited text no. 20
Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Sci Rep 2019;9:1-12.  Back to cited text no. 21
Swain S, Ewer M, Viale G, Delaloge S, Ferrero JM, Verrill M, et al. Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): A phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018;29:646-53.  Back to cited text no. 22
Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, et al. Survival outcomes of the NeoALTTO study (BIG 1-06): Updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019;118:169-77.  Back to cited text no. 23
Xu B, Wang J, Zhang Q, Liu Y, Feng JF, Wang W, et al. An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer. Am Soc Clin Oncol 2018;1028-1028.  Back to cited text no. 24